Drugs / QLS1317
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07552376 | May 2026 → Jun 2028 expected | — | Shanghai Qilu Pharmaceutical Research and Development Center LTD | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS1317 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07552376 ↗ |